Clinical trial · Interventional
Quality of Life and Cognitive Functioning in Patients With Glial Tumors
Quality of Life and Cognitive Functioning as Prognostic Factor in Glial Tumours
NCT07416838CI-TRIAL-00103598completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to introduce appropriate assessment instruments and to define patients with gliomas according to cognitive functioning and quality of life. The study will evaluate cognitive functioning as a prognostic factor for survival in patients with glial tumors and will support optimization of treatment strategies to improve patients' quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glial Tumors | Glioma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cognitive Functioning and Quality of Life Assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Glioma Patients
- description
- Patients with glial tumors assessed for quality of life and cognitive functioning as prognostic factors.
- interventionNames
- Other: Cognitive Functioning and Quality of Life Assessment
Primary outcomes (1)
- measure
- Change in Quality of Life Score (EORTC QLQ-C30 and QLQ-BN20)
- timeFrame
- Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months
- description
- Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer questionnaires EORTC QLQ-C30 and the brain cancer module EORTC QLQ-BN20. Scores range from 0 to 100 points. The outcome will be reported as mean change in questionnaire score (points) from baseline to each follow-up assessment.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult participants (≥18 years) * Patients with histologically confirmed glial tumour * Ability to understand the study procedures and provide written informed consent * Ability to complete quality of life questionnaires and cognitive testing Exclusion Criteria: * Age \<18 years * Inability to provide informed consent * Severe cognitive impairment or clinical condition preventing completion of questionnaires and cognitive testing * Insufficient language proficiency to complete the questionnaires and neuropsychological testing
References
Publications (0)
Data not yet available
No reference posted for this study.